Anixa Biosciences Submits Amendment To Protocol Amendment For CAR-T Trial
Portfolio Pulse from Benzinga Newsdesk
Anixa Biosciences has submitted an amendment to its CAR-T trial protocol, allowing a second dose of CAR-T therapy for suitable patients. This development could enhance treatment efficacy and patient outcomes.
September 30, 2024 | 12:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Anixa Biosciences has submitted an amendment to its CAR-T trial protocol, which will allow a second dose of CAR-T therapy for suitable patients. This could potentially improve treatment efficacy and patient outcomes.
The amendment to allow a second dose of CAR-T therapy could lead to better treatment outcomes, which is a positive development for Anixa Biosciences. This could enhance the company's reputation in the biotech field and potentially lead to increased investor interest.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100